# TT Electronics launch ground-breaking COVID-19 screening device

- Link: https://www.directorstalkinterviews.com/tt-electronics-launch-ground-breaking-covid-19-screening-device/412857560
- Published: 2020-09-10T07:23:07+01:00
- Author: Giles Arbor

**TT Electronics plc** ([LON:TTG](https://www.directorstalkinterviews.com/company/tt-electronics-plc/ttg.l))
has noted the announcement made today by iAbra in relation to the successful trial
and launch of Virolens®, its COVID-19 screening device. TT has been working with
British start up iAbra, and its partners including Intel, to design, develop and
test the prototype Virolens® system and to specify and design the manufacturing 
processes for its commercial launch.  

**Description of the Virolens® screening device**

The Virolens® COVID-19 screening device uses microscopic holographic imaging and
artificial intelligence (AI) software technology to detect the presence of the COVID-
19 virus from a non-intrusive saliva swab test within 20 seconds. The device does
not need to be administered by healthcare professionals and is expected to be used
in airports, offices, sports venues and many other locations where people need to
be in close proximity to each other.

Virolens® will enable safer access for everyone to places of work, transport and
events by providing a quick, easy, repeatable and low-cost COVID-19 test, allowing
hundreds of tests per machine each day. It will allow people to get on with their
everyday lives in the knowledge they are in a safe environment. In partnership with
Heathrow Airport, the system has successfully completed a first round of testing
and is about to embark on clinical trials which would be necessary for it to be 
certified for medical use.

**Initial commercial launch and potential**

TT has been appointed exclusive manufacturing partner for the commercial launch 
of Virolens®, which incorporates a number of TT proprietary products. TT has received
initial orders for devices and testing cartridges which will be delivered to potential
launch customers  in September and October 2020 with a value of circa £2 million.
Whilst the range of potential outcomes remains very broad, as an early indication
of the potential value of Virolens to TT, iAbra has indicated its intent to purchase
further devices and cartridges with associated revenue to TT of circa £280 million.
This is based on expressions of interest from more than a dozen end customers whose
assessment of Virolens® are at varying stages. This additional revenue is dependent
on iAbra’s end customers converting their expressions of interest into firm orders
and subject to Virolens® meeting regulatory authority requirements. Delivery of 
these further orders could commence in Q4 2020 and would continue into 2021.

**Selection of TT as a Virolens® partner**

iAbra is a technology company founded in 2010 and headquartered in Bedfordshire,
UK.  It has been developing neural network image analysis software for 10 years 
with applications in autonomous driving already in production. Virolens® is based
on the new application of this existing technology and has been developed in partnership
with TT and powered by Intel. TT was selected as the design and manufacturing partner
because of its ability to develop an idea from concept into a fully functioning 
machine, which can be produced in volume. TT’s engineering expertise and sub-system
product capability, coupled with its global manufacturing footprint, have been a
significant contributor to the rapid development of iAbra’s concept design to the
point of announcement today.

**Manufacturing in TT’s Hartlepool, UK facility**

TT will manufacture Virolens® at its Hartlepool, UK facility, part of its Power 
and Connectivity division, for this launch phase. TT will invest up to £5 million
to support this phase of the programme and the launch of Virolens® globally. Additional
device production and cartridge assembly may also take place at other TT locations,
as required.

> **Commenting Richard Tyson, TT Electronics Chief Executive Officer said:**
> “I am proud that we are a core part of the team behind the ground-breaking Virolens
> ® programme. This project is evidence of the success of our strategy to position
> the business in higher technology, structural growth markets, using our engineering
> expertise to develop products in collaboration with our customers.
> Virolens® has the potential to be a major step forward in dealing with the impact
> of the COVID-19 pandemic, by allowing safer access to places of work, transport
> and events.  TT’s leading-edge products and flexible manufacturing capabilities
> provide significant support to critical aspects of the Virolens® device.  
> This programme also has the potential to deliver a step change in TT’s organic
> growth and to accelerate the achievement of our target operating margins. Assuming
> the launch is successful,  there are significant opportunities around the world
> for further orders.”

Share on:
